Search

Your search keyword '"DE PLACIDO, SABINO"' showing total 1,528 results
Start Over Author "DE PLACIDO, SABINO"
1,528 results on '"DE PLACIDO, SABINO"'

55. Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis

Author

Necchi, Andrea, Pond, Gregory R., Raggi, Daniele, Ottenhof, Sarah R., Djajadiningrat, Rosa S., Horenblas, Simon, Khoo, Vincent, Hakenberg, Oliver W., Draeger, Desiree, Protzel, Chris, Heidenreich, Axel, Haidl, Friederike, Eigl, Bernie J., Nappi, Lucia, Matsumoto, Kazumasa, Vaishampayan, Ulka, Woods, Michael E., Salvioni, Roberto, Nicolai, Nicola, Catanzaro, Mario, Giannatempo, Patrizia, Geynisman, Daniel M., Preto, Mirko, Xylinas, Evanguelos, Milowsky, Matthew I., De Placido, Sabino, Di Lorenzo, Giuseppe, and Sonpavde, Guru

Published
2017
Full Text
View/download PDF

56. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

57. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

Author

Bonotto, Marta, Gerratana, Lorenzo, Di Maio, Massimo, De Angelis, Carmine, Cinausero, Marika, Moroso, Stefano, Milano, Monica, Stanzione, Brigida, Gargiulo, Piera, Iacono, Donatella, Minisini, Alessandro Marco, Mansutti, Mauro, Fasola, Gianpiero, De Placido, Sabino, Arpino, Grazia, and Puglisi, Fabio

Published
2017
Full Text
View/download PDF

58. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

Author

Lambertini, Matteo, Ceppi, Marcello, Cognetti, Francesco, Cavazzini, Giovanna, De Laurentiis, Michele, De Placido, Sabino, Michelotti, Andrea, Bisagni, Giancarlo, Durando, Antonio, Valle, Enrichetta, Scotto, Tiziana, De Censi, Andrea, Turletti, Anna, Benasso, Marco, Barni, Sandro, Montemurro, Filippo, Puglisi, Fabio, Levaggi, Alessia, Giraudi, Sara, Bighin, Claudia, Bruzzi, Paolo, and Del Mastro, Lucia

Published
2017
Full Text
View/download PDF

59. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, De Placido, Sabino, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Published
2020
Full Text
View/download PDF

60. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

Author

Caputo, Roberta, Cazzaniga, Marina Elena, Sbrana, Andrea, Torrisi, Rosalba, Paris, Ida, Giordano, Monica, Montesarchio, Vincenzo, Guarneri, Valentina, Amaducci, Laura, Bilancia, Domenico, Cilenti, Giuseppina, Fabi, Alessandra, Collovà, Elena, Schirone, Alessio, Bonizzoni, Erminio, Celio, Luigi, De Placido, Sabino, and De Laurentiis, Michelino

Published
2020
Full Text
View/download PDF

61. Machine Learning and Texture Analysis of [ 18 F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients.

Author

Hakkak Moghadam Torbati, Armin, Pellegrino, Sara, Fonti, Rosa, Morra, Rocco, De Placido, Sabino, and Del Vecchio, Silvana

Subjects
TEXTURE analysis (Image processing), NON-small-cell lung carcinoma, MACHINE learning, COMPUTED tomography, CANCER patients
Abstract

The aim of our study was to predict the occurrence of distant metastases in non-small-cell lung cancer (NSCLC) patients using machine learning methods and texture analysis of 18F-labeled 2-deoxy-d-glucose Positron Emission Tomography/Computed Tomography {[18F]FDG PET/CT} images. In this retrospective and single-center study, we evaluated 79 patients with advanced NSCLC who had undergone [18F]FDG PET/CT scan at diagnosis before any therapy. Patients were divided into two independent training (n = 44) and final testing (n = 35) cohorts. Texture features of primary tumors and lymph node metastases were extracted from [18F]FDG PET/CT images using the LIFEx program. Six machine learning methods were applied to the training dataset using the entire panel of features. Dedicated selection methods were used to generate different combinations of five features. The performance of selected machine learning methods applied to the different combinations of features was determined using accuracy, the confusion matrix, receiver operating characteristic (ROC) curves, and area under the curve (AUC). A total of 104 and 78 lesions were analyzed in the training and final testing cohorts, respectively. The support vector machine (SVM) and decision tree methods showed the highest accuracy in the training cohort. Seven combinations of five features were obtained and introduced in the models and subsequently applied to the training and final testing cohorts using the SVM and decision tree. The accuracy and the AUC of the decision tree method were higher than those obtained with the SVM in the final testing cohort. The best combination of features included shape sphericity, gray level run length matrix_run length non-uniformity (GLRLM_RLNU), Total Lesion Glycolysis (TLG), Metabolic Tumor Volume (MTV), and shape compacity. The combination of these features with the decision tree method could predict the occurrence of distant metastases with an accuracy of 74.4% and an AUC of 0.63 in NSCLC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

62. Aromatase inhibitors: the journey from the state of the art to clinical open questions.

Author

Generali, Daniele, Berardi, Rossana, Caruso, Michele, Cazzaniga, Marina, Garrone, Ornella, Minchella, Ida, Paris, Ida, Pinto, Carmine, and De Placido, Sabino

Subjects
AROMATASE inhibitors, METASTATIC breast cancer, BONE health, CARDIOVASCULAR diseases, PATIENT participation, OPEN-ended questions, HORMONE receptor positive breast cancer
Abstract

Breast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The authors reviewed the available literature and defined state-of-the-art AI management. This study was designed to assist clinicians in addressing the need to equally weigh patients' needs and disease control rates in their everyday clinical practice. Today, AIs play a central role in the treatment of hormone receptor-positive breast cancer. In this study, an expert panel reviewed the literature on the use of AIs, discussing the evolution of their use in various aspects of breast cancer, from pre- and postmenopausal early breast cancer to metastatic breast cancer, along with their management regarding efficacy and toxicity. Given the brilliant results that have been achieved in improving survival in everyday clinical practice, clinicians need to address their concerns about therapy duration and the adverse effects they exert on bone health, the cardiovascular system, and metabolism. Currently, in addition to cancer treatment, patient engagement is crucial for improving adherence to therapy and supporting patients' quality of life, especially in a selected subset of patients, such as those receiving an extended adjuvant or combination with targeted therapies. A description of modern technologies that contribute to this important goal is provided. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

63. Coefficient of Variation in Metastatic Lymph Nodes Determined by 18 F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors.

Author

Pellegrino, Sara, Fonti, Rosa, Vallone, Carlo, Morra, Rocco, Matano, Elide, De Placido, Sabino, and Del Vecchio, Silvana

Subjects
LUNG cancer, STATISTICS, LOG-rank test, LYMPH nodes, METASTASIS, POSITRON emission tomography computed tomography, HEALTH outcome assessment, RADIOPHARMACEUTICALS, KAPLAN-Meier estimator, DEOXY sugars, PROPORTIONAL hazards models, OVERALL survival
Abstract

Simple Summary: Lung cancer is the leading cause of cancer-related death worldwide. The 18F-FDG PET/CT scan is used daily for the diagnosis and staging of lung cancer. The heterogeneity of 18F-FDG uptake inside tumor lesions may have prognostic implications for lung cancer patients. Therefore, we tested whether an index of heterogeneity such as the coefficient of variation (CoV), determined in both metastatic lymph nodes and primary tumors, can predict overall survival of lung cancer patients. We found that a combination of CoV of targeted lymph nodes with CoV of primary tumors in each patient provides a more accurate prognostic stratification of lung cancer allowing risk-adapted therapy in individual patients. Purpose The aim of the present study was to test whether the coefficient of variation (CoV) of 18F-FDG PET/CT images of metastatic lymph nodes and primary tumors may predict clinical outcome in patients with advanced non-small cell lung cancer (NSCLC). Materials and Methods Fifty-eight NSCLC patients who had undergone 18F-FDG PET/CT at diagnosis were evaluated. SUVmax, SUVmean, CoV, MTV and TLG were determined in targeted lymph nodes and corresponding primary tumors along with Total MTV (MTVTOT) and Whole-Body TLG (TLGWB) of all malignant lesions. Univariate analysis was performed using Cox proportional hazards regression whereas the Kaplan–Meier method and log-rank tests were used for survival analysis. Results Fifty-eight metastatic lymph nodes were analyzed and average values of SUVmax, SUVmean, CoV, MTV and TLG were 11.89 ± 8.54, 4.85 ± 1.90, 0.37 ± 0.16, 46.16 ± 99.59 mL and 256.84 ± 548.27 g, respectively, whereas in primary tumors they were 11.92 ± 6.21, 5.47 ± 2.34, 0.36 ± 0.14, 48.03 ± 64.45 mL and 285.21 ± 397.95 g, respectively. At univariate analysis, overall survival (OS) was predicted by SUVmax (p = 0.0363), SUVmean (p = 0.0200) and CoV (p = 0.0139) of targeted lymph nodes as well as by CoV of primary tumors (p = 0.0173), MTVTOT (p = 0.0007), TLGWB (p = 0.0129) and stage (p = 0.0122). Using Kaplan–Meier analysis, OS was significantly better in patients with CoV of targeted lymph nodes ≤ 0.29 than those with CoV > 0.29 (p = 0.0147), meanwhile patients with CoV of primary tumors > 0.38 had a better prognosis compared to those with CoV ≤ 0.38 (p = 0.0137). Finally, we combined the CoV values of targeted lymph nodes and primary tumors in all possible arrangements and a statistically significant difference was found among the four survival curves (p = 0.0133). In particular, patients with CoV of targeted lymph nodes ≤ 0.29 and CoV of primary tumors > 0.38 had the best prognosis. Conclusions The CoV of targeted lymph nodes combined with the CoV of primary tumors can predict prognosis of NSCLC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

64. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.

Author

Cazzaniga, Marina Elena, Pronzato, Paolo, Amoroso, Domenico, Bernardo, Antonio, Biganzoli, Laura, Bisagni, Giancarlo, Blasi, Livio, Bria, Emilio, Cognetti, Francesco, Crinò, Lucio, De Laurentiis, Michelino, Del Mastro, Lucia, De Placido, Sabino, Beano, Alessandra, Ferraù, Francesco, Foladore, Silva, Forcignanò, Rosachiara, Gamucci, Teresa, Garrone, Ornella, and Gennari, Alessandra

Subjects
CONFIDENCE intervals, ONCOGENES, METASTASIS, ANTINEOPLASTIC agents, HYDROCARBONS, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, CELL lines, BEVACIZUMAB, ODDS ratio, PROGRESSION-free survival, BREAST tumors, LONGITUDINAL method, OVERALL survival, EVALUATION
Abstract

Simple Summary: Breast cancer is one of the most common oncological diseases among women in Western Countries and Italy as well. GIM 13-AMBRA is a patient journey study regarding how the prognosis of metastatic breast cancer patients has changed in the last decades as a result of the introduction of new drugs in clinical practice. This study also provides information regarding the different natural histories of breast cancer according to the presence or absence of hormone receptors and HER2 receptors. GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

65. Supplementary Data DS1 from Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Author

Arpino, Grazia, primary, de la Haba Rodríguez, Juan, primary, Ferrero, Jean-Marc, primary, De Placido, Sabino, primary, Osborne, C. Kent, primary, Klingbiel, Dirk, primary, Revelant, Valentine, primary, Wohlfarth, Christine, primary, Poppe, Raf, primary, and Rimawi, Mothaffar F., primary

Published
2023
Full Text
View/download PDF

66. Data from Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Author

Arpino, Grazia, primary, de la Haba Rodríguez, Juan, primary, Ferrero, Jean-Marc, primary, De Placido, Sabino, primary, Osborne, C. Kent, primary, Klingbiel, Dirk, primary, Revelant, Valentine, primary, Wohlfarth, Christine, primary, Poppe, Raf, primary, and Rimawi, Mothaffar F., primary

Published
2023
Full Text
View/download PDF

67. Data from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Author

Giordano, Antonio, primary, Gao, Hui, primary, Anfossi, Simone, primary, Cohen, Evan, primary, Mego, Michal, primary, Lee, Bang-Ning, primary, Tin, Sanda, primary, De Laurentiis, Michele, primary, Parker, Charla A., primary, Alvarez, Ricardo H., primary, Valero, Vicente, primary, Ueno, Naoto T., primary, De Placido, Sabino, primary, Mani, Sendurai A., primary, Esteva, Francisco J., primary, Cristofanilli, Massimo, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

68. Table S2 from Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells

Author

Montanari, Micaela, primary, Carbone, Maria Rita, primary, Coppola, Luigi, primary, Giuliano, Mario, primary, Arpino, Grazia, primary, Lauria, Rossella, primary, Nardone, Agostina, primary, Leccia, Felicia, primary, Trivedi, Meghana V., primary, Garbi, Corrado, primary, Bianco, Roberto, primary, Avvedimento, Enrico V., primary, De Placido, Sabino, primary, and Veneziani, Bianca Maria, primary

Published
2023
Full Text
View/download PDF

69. Supplementary table 3 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

70. Figure S2 from Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells

Author

Montanari, Micaela, primary, Carbone, Maria Rita, primary, Coppola, Luigi, primary, Giuliano, Mario, primary, Arpino, Grazia, primary, Lauria, Rossella, primary, Nardone, Agostina, primary, Leccia, Felicia, primary, Trivedi, Meghana V., primary, Garbi, Corrado, primary, Bianco, Roberto, primary, Avvedimento, Enrico V., primary, De Placido, Sabino, primary, and Veneziani, Bianca Maria, primary

Published
2023
Full Text
View/download PDF

71. Data from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

72. Legend to Supplemental Figures from Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells

Author

Montanari, Micaela, primary, Carbone, Maria Rita, primary, Coppola, Luigi, primary, Giuliano, Mario, primary, Arpino, Grazia, primary, Lauria, Rossella, primary, Nardone, Agostina, primary, Leccia, Felicia, primary, Trivedi, Meghana V., primary, Garbi, Corrado, primary, Bianco, Roberto, primary, Avvedimento, Enrico V., primary, De Placido, Sabino, primary, and Veneziani, Bianca Maria, primary

Published
2023
Full Text
View/download PDF

73. Supplementary Figure 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

74. Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

75. Supplementary Figure 1 from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Author

Giordano, Antonio, primary, Gao, Hui, primary, Anfossi, Simone, primary, Cohen, Evan, primary, Mego, Michal, primary, Lee, Bang-Ning, primary, Tin, Sanda, primary, De Laurentiis, Michele, primary, Parker, Charla A., primary, Alvarez, Ricardo H., primary, Valero, Vicente, primary, Ueno, Naoto T., primary, De Placido, Sabino, primary, Mani, Sendurai A., primary, Esteva, Francisco J., primary, Cristofanilli, Massimo, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

76. Supplementary table 4 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

77. Data from Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells

Author

Montanari, Micaela, primary, Carbone, Maria Rita, primary, Coppola, Luigi, primary, Giuliano, Mario, primary, Arpino, Grazia, primary, Lauria, Rossella, primary, Nardone, Agostina, primary, Leccia, Felicia, primary, Trivedi, Meghana V., primary, Garbi, Corrado, primary, Bianco, Roberto, primary, Avvedimento, Enrico V., primary, De Placido, Sabino, primary, and Veneziani, Bianca Maria, primary

Published
2023
Full Text
View/download PDF

78. Supplementary Figure Legend from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Author

Giordano, Antonio, primary, Gao, Hui, primary, Anfossi, Simone, primary, Cohen, Evan, primary, Mego, Michal, primary, Lee, Bang-Ning, primary, Tin, Sanda, primary, De Laurentiis, Michele, primary, Parker, Charla A., primary, Alvarez, Ricardo H., primary, Valero, Vicente, primary, Ueno, Naoto T., primary, De Placido, Sabino, primary, Mani, Sendurai A., primary, Esteva, Francisco J., primary, Cristofanilli, Massimo, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

79. Supplementary table 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

80. Supplementary table 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

81. Legend for supplementay figures from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

82. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo Md Phd M., Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, Del Mastro, Lucia, Lambertini, Matteo Md Phd M., Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Abstract

Background: Prior exposure to adjuvant endocrine therapy (ET) and timing to recurrence are crucial factors for first-line treatment choices in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) and in clinical trial eligibility, classifying metastatic HR+/HER2− BC as endocrine sensitive (ES) or primary (1ER)/secondary (2ER) resistant. However, this classification is largely based on expert opinion and no proper evidence exists to date to support its possible prognostic and clinical impact. Methods: This analysis included individual patient-level data from 4 adjuvant phase III randomized trials by the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) study groups. The impact of endocrine resistance/sensitivity classification on overall survival (mOS, defined as time between date of distant relapse and death) was assessed in both univariate and multivariate Cox proportional hazards models. Findings: Between November 1992 and July 2012, 9058 patients were randomized in 4 trials, of whom 6612 had HR+/HER2− BC. Median follow-up was 9.1 years (interquartile range [IQR] 5.6–15.0). In the whole cohort, disease-free survival and OS were 90.4% and 96.6% at 5 years, and 79.1% and 89.4% at 10 years, respectively. The estimated hazard of recurrence raised constantly during the first 15 years from diagnosis, being more pronounced during the first 2 years and less pronounced after year 7. Among the 493 patients with a distant relapse as first disease-free survival event and available date on ET completion, 72 (14.6%), 207 (42.0%) and 214 (43.4%) were classified as having 1ER, 2ER and ES, respectively. Median follow-up from diagnosis of a distant relapse was 3.8 years (IQR 1.6–7.5). Patients with 1ER were significantly more likely to be younger, to have N2/N3 nodal status, grade 3 tumours and to develop visceral metastases. Site of first distant relapse was significantly different between the 3 groups (p = 0.005). In patients with 1ER, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

85. Supplementary Methods from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

86. Supplementary Table 2 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

87. Supplementary Figure 6 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

88. Supplementary Figure Legend from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

89. Supplementary Figure 4 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

90. Supplementary Figure 3 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

92. Supplementary Figure 1 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

93. Supplementary Figure 2 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

94. Supplementary Table 1 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

95. Supplementary Figure 5 from Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Author

Rosa, Roberta, primary, Marciano, Roberta, primary, Malapelle, Umberto, primary, Formisano, Luigi, primary, Nappi, Lucia, primary, D'Amato, Claudia, primary, D'Amato, Valentina, primary, Damiano, Vincenzo, primary, Marfè, Gabriella, primary, Del Vecchio, Silvana, primary, Zannetti, Antonella, primary, Greco, Adelaide, primary, De Stefano, Alfonso, primary, Carlomagno, Chiara, primary, Veneziani, Bianca Maria, primary, Troncone, Giancarlo, primary, De Placido, Sabino, primary, and Bianco, Roberto, primary

Published
2023
Full Text
View/download PDF

96. Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype

Author

Caltavituro, Aldo, primary, Buonaiuto, Roberto, additional, Pietroluongo, Erica, additional, Morra, Rocco, additional, Salomone, Fabio, additional, De Placido, Pietro, additional, Pagliuca, Martina, additional, Vaia, Angelo, additional, Ottaviano, Margaret, additional, Tortora, Marianna, additional, De Placido, Sabino, additional, Palmieri, Giovannella, additional, and Giuliano, Mario, additional

Published
2023
Full Text
View/download PDF

97. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Author

Pignata, Sandro, primary, Scambia, Giovanni, additional, Schettino, Clorinda, additional, Arenare, Laura, additional, Pisano, Carmela, additional, Lombardi, Davide, additional, De Giorgi, Ugo, additional, Andreetta, Claudia, additional, Cinieri, Saverio, additional, De Angelis, Carmine, additional, Priolo, Domenico, additional, Casanova, Claudia, additional, Rosati, Marta, additional, Greco, Filippo, additional, Zafarana, Elena, additional, Schiavetto, Ilaria, additional, Mammoliti, Serafina, additional, Cecere, Sabrina Chiara, additional, Salutari, Vanda, additional, Scalone, Simona, additional, Farolfi, Alberto, additional, Di Napoli, Marilena, additional, Lorusso, Domenica, additional, Gargiulo, Piera, additional, Califano, Daniela, additional, Russo, Daniela, additional, Spina, Anna, additional, De Cecio, Rossella, additional, Chiodini, Paolo, additional, Perrone, Francesco, additional, Accinno, Valentina, additional, Altavilla, Chiara, additional, Antonelli, Giovanna, additional, Artioli, Grazia, additional, Avola, Francesco, additional, Barbara, Bonifacio, additional, Barbato, Valentina, additional, Bartoletti, Michele, additional, Bevilacqua, Simona, additional, Bordonaro, Roberto, additional, Borghese, Oriana, additional, Buonfanti, Gaetano, additional, Camarda, Floriana, additional, Canzanella, Giuliana, additional, Carbone, Vittoria, additional, Carbone, Maria Rita, additional, Carlo Stella, Giulia, additional, Cassani, Chiara, additional, Castagna, Fabrizio, additional, Cattaneo, Monica, additional, Cinefra, Margherita, additional, Colombo, Nicoletta, additional, Corsetti, Serena, additional, Dall'Agata, Monia, additional, D'Amico, Maria, additional, Daniele, Gennaro, additional, De Marino, Elvira, additional, De Matteis, Giovanni, additional, De Placido, Sabino, additional, Del Bene, Gabriella, additional, Del Giudice, Antonia, additional, Del Monte, Francesca, additional, Del Sesto, Michele, additional, Donini, Maddalena, additional, Drudi, Giuliana, additional, Falcone, Gianluca, additional, Favaretto, Adolfo, additional, Ferrera, Giulia, additional, Florio, Manuela, additional, Forestieri, Valeria, additional, Gallo, Maria Stella, additional, Gallo, Ciro, additional, Garibaldi, Francesca, additional, Gerevini, Fabiana, additional, Ghizzoni, Viola, additional, Giganti, Maria Olga, additional, Gimigliano, Anna, additional, Giudice, Elena, additional, Gnocchi, Nicoletta, additional, Gravina, Adriano, additional, Greggi, Stefano, additional, Iaia, Maria Laura, additional, Ilardi, Annalisa, additional, Iovine, Gelsomina, additional, Ippoliti, Gabriella, additional, Irollo, Giulia, additional, Isidori, Ilenia, additional, Lapresa, Mariateresa, additional, Lavenia, Giuseppe, additional, Longhitano, Laura, additional, Lucia, Bortot, additional, Luzi, Gabriella, additional, Mariano, Sara, additional, Marino, Valentina, additional, Marrapese, Giovanna, additional, Martino, Marilena, additional, Matocci, Roberta, additional, Mazzoni, Enrica, additional, Mercuri, Daniela, additional, Mirto, Maria, additional, Mollo, Giovanna, additional, Montinaro, Abbondanza, additional, Moscatelli, Marta, additional, Mosconi, Anna Maria, additional, Musacchio, Lucia, additional, Nanni, Nicoletta, additional, Natalucci, Pamela, additional, Nicoloso, Milena Sabrina, additional, Orditura, Michele, additional, Parma, Gabriella Maria, additional, Passalacqua, Rodolfo, additional, Pelone, Michela, additional, Perri, Maria Teresa, additional, Perrucci, Bruno, additional, Piancastelli, Alessandra, additional, Piccirillo, Maria Carmela, additional, Piccolo, Antonio, additional, Pignata, Sandro, additional, Rapisardi, Stefania, additional, Ravaglia, Giorgia, additional, Ribecco, Teresa, additional, Ricci, Caterina, additional, Roccio, Marianna, additional, Romano, Fiorella, additional, Sambataro, Daniela, additional, Savio, Alfonso, additional, Sbriglia, Ada, additional, Scaffa, Cono, additional, Sergi, Concetta, additional, Sgandurra, Francesca, additional, Sorio, Roberto, additional, Stabile, Stefano, additional, Tabaro, Gianna, additional, Tambaro, Margherita, additional, Tamberi, Stefano, additional, Tecchiato, Angelica, additional, Trujillo, Angela Maria, additional, and Zaccarelli, Eleonora, additional

Published
2023
Full Text
View/download PDF

98. Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic

Author

Pietroluongo, Erica, primary, De Placido, Pietro, additional, Picozzi, Fernanda, additional, Morra, Rocco, additional, Tortora, Marianna, additional, Del Deo, Vitantonio, additional, Montella, Liliana, additional, Palmieri, Giovannella, additional, Buonomo, Antonio Riccardo, additional, De Placido, Sabino, additional, Gentile, Ivan, additional, and Giuliano, Mario, additional

Published
2023
Full Text
View/download PDF

100. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

Author

Gampenrieder, S.P., primary, Dezentjé, V., additional, Lambertini, M., additional, de Nonneville, A., additional, Marhold, M., additional, Le Du, F., additional, Cortés Salgado, A., additional, Alpuim Costa, D., additional, Vaz Batista, M., additional, Chic Ruché, N., additional, Tinchon, C., additional, Petzer, A., additional, Blondeaux, E., additional, Del Mastro, L., additional, Targato, G., additional, Bertucci, F., additional, Gonçalves, A., additional, Viret, F., additional, Bartsch, R., additional, Mannsbart, C., additional, Deleuze, A., additional, Robert, L., additional, Saavedra Serrano, C., additional, Gion Cortés, M., additional, Sampaio-Alves, M., additional, Vitorino, M., additional, Pecen, L., additional, Singer, C., additional, Harbeck, N., additional, Rinnerthaler, G., additional, Greil, R., additional, Balic, Marija, additional, Heibl, Sonja, additional, Zabernigg, August Felix, additional, Egle, Daniel, additional, Sandholzer, Margit, additional, Roitner, Florian, additional, Andel, Johannes, additional, Pichler, Petra, additional, Hager, Christopher, additional, Knauer, Michael, additional, Hubalek, Michael, additional, Bighin, Claudia, additional, De Laurentiis, Michelino, additional, De Placido, Sabino, additional, Puglisi, Fabio, additional, Boni, Luca, additional, de Gregorio, Amelie, additional, Degenhardt, Tom, additional, Formisano, Luigi, additional, Beelen, Karin, additional, Robinson, Timothy, additional, Fitzpatrick, Amanda, additional, Dieras, Veronique, additional, Muller, Volkmar, additional, Gennari, Alessandra, additional, Linn, Sabine, additional, Braga, Sofia, additional, Cortes, Javier, additional, and Palmieri, Carlo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results